Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia: present status

E Montserrat1, C Rozman

  • 1Postgraduate School of Hematology Farreras Valentí, Department of Medicine, University of Barcelona, Hospital Clinic, Spain.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1996
Same author

Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features?

Leukemia·1996
Same author

[Occult involvement of bone marrow in Hodgkin's disease: detection with magnetic resonance].

Medicina clinica·1996
Same author

[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].

Medicina clinica·1996
Same author

Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects.

Blood·1996
Same author

Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients.

Annals of hematology·1996
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Chronic lymphocytic leukemia (CLL), a common leukemia, has unknown causes but may involve genetic and environmental factors. Recent advances include purine analogs and bone marrow transplants, improving patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Epidemiology

Background:

  • Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries.
  • The etiology of CLL remains unknown, with current research suggesting potential genetic and environmental influences.
  • Disease progression involves leukemic cell accumulation and immune disturbances, impacting patient prognosis.

Purpose of the Study:

  • To review the current understanding of Chronic lymphocytic leukemia (CLL) etiology and clinical presentation.
  • To summarize the evolving treatment strategies for CLL, including traditional and novel therapeutic approaches.
  • To highlight recent advances in CLL management and their potential impact on patient outcomes.

Main Methods:

  • Literature review of epidemiological data and clinical studies on CLL.

Related Experiment Videos

  • Analysis of treatment outcomes associated with various therapeutic modalities.
  • Evaluation of emerging therapies such as purine analogs and bone marrow transplantation.

    • Main Results:

    • CLL etiology is multifactorial, with genetic and environmental factors implicated.
    • Treatment decisions for CLL are stage-dependent, with early stages often managed by observation.
    • Advanced CLL stages necessitate treatment, with purine analogs and bone marrow transplants showing promise.

    Conclusions:

    • Recent therapeutic advancements, including purine analogs and bone marrow transplants, offer improved outcomes for CLL patients.
    • The management of CLL is shifting towards more targeted and effective therapies.
    • Continued research is crucial for further improving the prognosis and treatment of Chronic lymphocytic leukemia.